

YEVROSIYO PEDIATRIYA AXBOROTNOMASI/ЕВРАЗИЙСКИЙ ВЕСТНИК ПЕДИАТРИИ



# **YEVROSIYO PEDIATRIYA AXBOROTNOMASI**

# **ЕВРАЗИЙСКИЙ ВЕСТНИК ПЕДИАТРИИ**

TIBBIY ILMIY-INNOVATSION JURNAL  
МЕДИЦИНСКИЙ НАУЧНО-ИННОВАЦИОННЫЙ ЖУРНАЛ



**2 (13)**  
**2022**

ISSN 2181-1954  
ESSN 2181-1962

**Главные редакторы-**

**Сопредседатели редакционной коллегии:**

Б.Т. ДАМИНОВ,  
Д.О. ИВАНОВ

АБЗАЛОВА Ш. Р. (Ташкент)  
АЙТОВ К.А. (Иркутск, Россия)  
АЛЕКСАНДРОВИЧ Ю.С. (Санкт-Петербург, Россия)  
АКИЛОВ Х.А. (Ташкент)  
АЛИЕВ М.М. (Ташкент)  
АМОНОВ Ш.Э. (Ташкент)  
АРИПОВ А.Н. (Ташкент)  
АШУРОВА Д.Т. (Ташкент)  
БУЗРУКОВ Б.Т. (Ташкент)  
ВАЛИЕВ А.Р. (Ташкент)  
ГУЛЯМОВ С.С. (Ташкент)  
ДАМИНОВА Ш.Б. (Ташкент)  
ДЕХКОНОВ К.А. (Ташкент)  
ДУДАРЕВ М.В. (Россия)  
ЗАСЛАВСКИЙ Д.В. (Россия)  
ИСКАНДАРОВА А.И. (Ташкент)  
ИСКАНДАРОВА Ш.Т. (Ташкент)  
ИСМАИЛОВ С.И. (Ташкент)  
КАРИЕВ Г.М. (Ташкент)  
МАДЖИДОВА Ё.Н. (Ташкент)  
ОХЛОПКОВ В.А. (Россия)  
ПОДКАМНЕВ А.В. (Санкт-Петербург, Россия)  
ПУЗЫРЕВ В.С. (Санкт-Петербург, Россия)  
РАХМАНКУЛОВА З.Ж. (Ташкент)  
РАХМАТУЛЛАЕВ А.А. (Ташкент)  
ФУЭНГ ЖИАО (Китай)  
СОБИРОВ М.А. (Ташкент)  
СОДИКОВА Г.К. (Ташкент)  
СОХАЧ А.Я. (Ставрополь, Россия)  
ТАДЖИЕВ Б.М. (Ташкент)  
ТАШМУХАМЕДОВА Ф.К. (Ташкент)  
ТИМЧЕНКО В.Н. (Санкт-Петербург, Россия)  
ХАЙТОВ К.Н. (Ташкент)  
ХАЙБУЛЛИНА З.Р. (Ташкент)  
ХАСАНОВ С.А. (Ташкент)  
ШАМАНСУРОВА Э.А. (Ташкент)  
ШАМСИЕВ Ф.М. (Ташкент)  
ШАРИПОВ А.М. (Ташкент)  
ШКЛЯЕВ А.Е. (Россия)  
ЮСУПАЛИЕВА Г.А. (Ташкент)  
ЮЛДАШЕВ И.Р. (Ташкент)  
ЭРГАШЕВ Н.Ш. (Ташкент)

**Публикация рекламы на коммерческой основе.**

**Ответственность за правильность рекламного текста несёт рекламодатель.**

**Рекламодатели предупреждены редакцией об ответственности за рекламу не зарегистрированных и не разрешенных к применению Министерством здравоохранения РУз лекарственных средств и предметов медицинского назначения.**

**Рукописи, фотографии, рисунки не рецензируются и не возвращаются авторам.**

**Авторы несут ответственность за достоверность и разрешение на публикацию излагаемых фактов, точность цифровых данных, правильность названий препаратов, терминов, литературных источников, имен и фамилий.**

**ЕВРОСИЁ ПЕДИАТРИЯ АХБОРОТНОМАСИ  
ЕВРАЗИЙСКИЙ ВЕСТНИК ПЕДИАТРИИ**

Тиббий илмий-инновацион журнал  
Медицинский научно-инновационный журнал

**Учредители:**

Ташкентский педиатрический медицинский институт  
Санкт-Петербургский государственный  
педиатрический медицинский университет

Зарегистрирован агентством информации и  
массовых коммуникации при Администрации Президента  
Республики Узбекистан 08.05. 2019 г.  
Свидетельство №1023

Журнал с 01.09. 2019 года включен в список  
иностраных журналов ВАК Республики  
Узбекистан. Протокол № 268/7 от 30.08. 2019 года.

**Заместители главного редактора:**

*Гулямов С.С. Орел В.И.*

**Ответственный секретарь:**

*Рузиев Ш.И.*

**Заведующий редакцией:**

*Дехконов К.А.*

**РЕДАКЦИОННЫЙ СОВЕТ**

АЛИМОВ А.В. (Ташкент)  
АСАДОВ Д.А. (Ташкент)  
АТАНИЯЗОВА А.А. (Нукус)  
АХМЕДОВА Д.И. (Ташкент)  
БОРОНБАЕВА Р.З. (Нур-Султан, Казахстан)  
ВАСИЛЕНКО В.С. (Санкт-Петербург, Россия)  
ДАМИНОВ Т.О. (Ташкент)  
ДЕВИЛ Д. (Рим, Италия)  
ДЖУМАШАЕВА К.А. (Кыргизистан)  
ИНОЯТОВА Ф.И. (Ташкент)  
НАБИЕВ З.Н. (Таджикистан)  
ОРЕЛ В.И. (Санкт-Петербург, Россия)  
ПЕВЕЛЕЦ К.В. (Санкт-Петербург, Россия)  
РИКАРДО С. (Вашингтон, США)  
КРАСИВИНА Д.А. (Санкт-Петербург, Россия)  
СТАРЦЕВ А.И. (Беларусь)  
ТУЙЧИЕВ Л.Н. (Ташкент)  
ЧОНГ ПЕНГ ЧУНГ (Сеул, Южная Корея)  
ШАДМАНОВ А.К. (Ташкент)  
ШАМСИЕВ А.М. (Самарканд)  
ЭНВЕР ХАСАНОГЛУ (Анкара, Турция)  
ЮЛДАШЕВА Н.Ю. (Великобритания)  
ЯКОВЛЕВ А.В. (Санкт-Петербург, Россия)

**Адрес редакции:**

100140 Республика Узбекистан

г. Ташкент ул. Богущамол, 223

тел: +99871 - 260-28-57;

факс: +998971 - 262 - 33-14;

www: [tashpmi.uz/ru/science/journal\\_pediatriy](http://tashpmi.uz/ru/science/journal_pediatriy)

**2(13) 2022**

**Апрель-июнь**

UDC 615.099.036.8: 618.2-055.27:616.9

RESULTS OF IMMUNOHISTOCHEMICAL STUDY OF LIVER DISEASES IN MATERNAL MORTALITY

E.A. Eshbayev

Tashkent Medical Academy, Republican Center for Pathological Anatomy

Resume

*Maternal mortality One of the most common complications observed during pregnancy today is liver failure. Among the main complications caused by this liver are intrahepatic cholestasis in pregnant women, liver damage associated with preeclampsia, which can lead to serious complications as a result of the development of acute fatty hepatitis in pregnant women. Evaluation of pathomorphological changes in the liver as a result of immunohistochemical examination is currently being evaluated for the first time in the country through this scientific work, and 20 patients were selected for this study from 3 different fatal diseases that underwent autopsy as a result of the above maternal diseases. Liver changes in these patients are assessed by immunohistochemical reagents Ki-67, Bcl-2, CD 20, CD3.*

*Key words: pregnancy, liver disease, cholestasis, hepatitis, cirrhosis, acute fatty hepatitis.*

ONALAR O'LIMIDA JIGAR KASALLIKLARINING IMMUNOGISTOKIMYOVIY TEKSHIRUV NATIJALARI

E.A. Eshbayev

Toshkent tibbiyot akademiyasi, Respublika patologik anatomiya markazi

Rezyume

*Onalar o'limi hozirgi kunda xomiladorlik vaktida kuzatiladigan eng ko'p asoratlardan biri jigar yetishmovchiligi xisoblanadi. Ushbu jigar olib keladigan asosiy asoratlardan homilador ayollarning intragepatik xolestazi, preeklampsiya bilan bog'liq jigar shikastlanishi, homilador ayollarning o'tkir yog' gepatozi rivojlanishi natijasida og'ir asoratlarga olib kelishi mumkin. Jigarda bo'ladigan patomorfologik o'zgarishlarni immunogistoximik tekshiruv usuli natijasida baholash hozirgi vaqtda Respublikamizda ilk bor ushbu ilmiy ish orqali baholanmoqda va ushbu tekshiruvni o'tkazish uchun yuqoridagi onalar o'limiga olib kelgan kasalliklar natijasida autopsiya amaliyoti o'tkazilgan 3 xil o'limga olib kelgan kasalliklardan 20 tadan bemorlar tanlab olingan. Ushbu bemorlardagi jigardagi o'zgarishlar immunogistokimyoviy kuyidagi reagentlar Ki-67, Bcl-2, CD 20, CD3 orqali baholanadi.*

*Kalit so'zlar: homiladorlik, jigar kasalliklari, xolestaz, gepatit, sirroz, o'tkir yog'li gepatoz.*

РЕЗУЛЬТАТЫ ИММУНОГИСТОХИМИЧЕСКОГО ИССЛЕДОВАНИЯ ЗАБОЛЕВАНИЙ ПЕЧЕНИ ПРИ МАТЕРИНСКОЙ СМЕРТНОСТИ

Э.А. Эшбаев

Ташкентская медицинская академия, Республиканский центр патологической анатомии

Резюме

*Одним из наиболее частых осложнений материнской смертности при беременности на сегодняшний день является печеночная недостаточность. Основными осложнениями, приводящими к данной печеночной недостаточности, являются внутриспеченочный холестаз у беременных, поражение печени, связанное с гестозом, и тяжелые осложнения, обусловленные развитием острого жирового гепатоза у беременных. Оценка патоморфологических изменений в печени в результате иммуногистохимического исследования в настоящее время проводится впервые в стране посредством данной научной работы. Из числа вступивших заболеваний отобрано 20 пациентов. Изменения печени у этих больных оценивают с помощью иммуногистохимических реактивов Ki-67, Bcl-2, CD 20, CD3.*

*Ключевые слова: беременность, заболевания печени, холестаз, гепатит, цирроз, острый жировой гепатоз.*

**Relevance**

Maternal mortality is one of the highest pregnancy rates to date. One of the most severe complications of maternal mortality in pregnant women is liver pathology. Excessive vomiting in pregnant women, intrahepatic cholestasis in pregnant women, liver damage associated with preeclampsia, the development of acute fatty hepatosis in pregnant women can lead to serious complications. The development of these pathological conditions in the liver confirms the high rate of perinatal mortality.

**Purpose:** Immunohistochemical study of specific morphological changes in liver tissue isolated at autopsy of patients who died from liver diseases during pregnancy, and the application of practical recommendations.

**Materials and methods:** Macroscopic, microscopic and immunohistochemical methods were used to study the liver of those who died from COVID-19 in the practice of the RPAC (Republican Pathological Anatomical Center) Ministry of Health of the Republic of Uzbekistan in 2020-2021. Clinical and anamnestic data were analyzed by analyzing the medical history and the autopsy report. Histological sections were

made from paraffin blocks made from spleen tissue obtained at autopsy and stained with hematoxylin-eosin stain. Histological preparations were examined under a trinocular light microscope and photomicrographs of the corresponding areas were taken.

**Research and discussion**

**Immunohistochemistry** - a diagnostic method for immunological and histochemical reactions - is one of the main methods of pathomorphological diagnosis, histologically (pathomorphologically) immunohistochemical examination of patients morphologically under a microscope was performed to verify and evaluate the results of antigen testing. The study is carried out to analyze various processes. To identify molecular structures in cells, study cellular localization, development of precancerous processes, monitor these processes, determine prognostic complications of the disease, determine tumor stages, determine treatment tactics, dynamic observation and treatment processes, the origin of tumors, this examination method is important for identifying potential groups risk.

**Table 1.**

**Functions of reagents in the cell**

№	Reagents	Reagent function
1	Ki-67	Sign of cell proliferative activity. Calculated as a percentage and indicates that the percentage is active, depending on the type of additional cells. This supplement is a reagent for disease prognosis. The higher the Ki-67, the more dangerous and faster the growth of the tumor.
2	Bcl-2	Bcl-2 is a protein reagent that prevents natural apoptosis.
3	CD 20	CD20 is a reagent found on the surface of B-lymphocytes. Human gene product - MC4A1. Participates in the activation and proliferation of B-lymphocytes.
4	CD3	CD3 is a polyprotein complex located on the surface of T-lymphocytes, a cellular complex that indicates the main level of activity of T-cell reagents.


**Patients who underwent immunohistochemical study for maternal mortality №-60**

№	Diseases	Quantity
1	Intrahepatic cholestasis	20 patients
2	Preeclampsia	20 patients
3	Fatty liver disease	20 patients

**Intrahepatic cholestasis**

Signs of proliferative activity of Ki-67 cells. Changes in the liver of patients who died as a result of intrahepatic cholestasis were assessed as low proliferative activity up to 10%, moderate proliferative activity 10-20% and high proliferative activity more than 20%. This


reagent is a reagent that indicates additional disease prognosis. The higher the Ki-67 value, the more it indicates the degree of danger and the rapid development of cells or tumors. In all 20 selected patients, the proliferative activity of Ki-67 ranged from 1 to 8%.



*Fig.1. The proliferative activity of the Ki-67 reagent in intrahepatic cholestasis is 3-5%. The Dab coloring is chromogenic. Lens 20-Eyepiece 40.*

**Bcl-2** is a protein reagent that prevents natural apoptosis. These reagents were evaluated positively and negatively. Liver changes in patients who died as a result of intrahepatic cholestasis were negative in all 20 patients examined with this reagent. **CD20** is a reagent found on the surface of B-lymphocytes. It is a reagent involved in the activation and proliferation of B-lymphocytes. These reagents


were evaluated positively and negatively. Inflammatory reactions in lymphocytes due to inflammation of the liver were assessed by positive and negative indicators. Positive reaction results were detected in all selected 20 patients. Chronic inflammation of the liver in patients who died as a result of intrahepatic cholestasis indicates an increase in the number of lymphocytes.



*Fig.2. Positive reaction of the CD20 reagent for liver B-lymphocytes in intrahepatic cholestasis. The Dab coloring is chromogenic. Lens 20-Eyepiece 40.*

**CD3** is a polyprotein complex located on the surface of T-lymphocytes, a cellular complex that indicates the main level of activity of T-cell reagents. These reagents were evaluated positively and

negatively. Immunohistochemical reactions in lymphocytes in liver inflammation were assessed by positive and negative indicators. Positive reaction results were detected in all 20 selected patients.




*Fig.3. Positive reaction of CD3 reagent to liver T-lymphocytes in intrahepatic cholestasis. The Dab coloring is chromogenic. Lens 20-Eyepiece 40.*

Summarizing the results of an immunohistochemical study of patients with intrahepatic cholestasis, the results of the Ki-67 reagent show that in all patients, the results of a mild positive reaction due to severe inflammation were observed in 1-8%. Bcl-2 reagent test showed a negative reaction in all patients. The

results of tests with CD20 and CD3 reagents showed that in intrahepatic cholestasis against the background of severe inflammation, a high concentration of lymphocytes around hepatocytes was observed, and all 20 patients had positive reactions to CD20 and CD3 reagents.

Diagram 1.

Results of immunohistochemical study in intrahepatic cholestasis №20



**Immunohistochemical changes in preeclampsia**

**Ki-67** is a sign of cell proliferative activity. Liver changes in patients who died from preeclampsia were assessed as low proliferative activity up to 10%, moderate proliferative activity 10-20% and high proliferative activity more than 20%. This reagent is a reagent that indicates additional disease prognosis. All 20 selected patients had indicators of Ki-67 proliferative activity in the range of 1-6 percent. Medium and high proliferative values were not found in the study.

**Bcl-2** is a protein reagent that prevents natural apoptosis. These reagent scores were evaluated

using both positive and negative scores. Liver changes in patients who died as a result of preeclampsia were 100% negative in all 20 patients examined with this reagent.

The level of inflammation of the liver **CD20** was assessed by the activation and proliferation of B-lymphocytes. These reagent values were determined by positive and negative values. Positive reaction results were detected in all 20 selected patients. Chronic inflammation of the liver in patients who died from preeclampsia indicates an increase in the number of lymphocytes.




Fig.4. Positive reaction of the CD3 reagent for liver T-lymphocytes in preeclampsia. The Dab coloring is chromogenic. Lens 20-Eyepiece 40.




Fig.5. Positive reaction of the CD20 reagent for liver B-lymphocytes in preeclampsia. The Dab coloring is chromogenic. Lens 20-Eyepiece 40.


CD3 is a cell complex that exhibits the main level of activity of T-lymphocytes. These reagents were evaluated positively and negatively. Positive reaction results were detected in all 20 selected patients with preeclampsia.

When summarizing the results of an immunohistochemical study of patients with preeclampsia, the results of the Ki-67 reagent showed that all patients had mild positive results,

i.e. up to 1-8%, there are no medium and high positive results. Bcl-2 reagent test showed a negative reaction in all patients. The results of tests with CD20 and CD3 reagents showed that in preeclampsia, a high concentration of lymphocytes around hepatocytes, leading to a strong inflammatory process around hepatocytes, led to a positive reaction to CD20 and CD3 reagents in all 20 patients.

Diagram 2.

Results of immunohistochemical study in preeclampsia №20



### Immunohistochemical changes in fatty liver disease

Ki-67 is a marker of cell proliferative activity, and changes in the liver of patients who died from fatty liver disease have been estimated as up to 10% with low proliferative activity, 10-20% with medium proliferative activity, and more than 20% with high proliferative activity. The results of the study of the proliferative activity of Ki-67 in the range of 2-8% were detected in all 20 selected patients. Medium and high proliferative values were not found in the study.

Results of a study with Bcl-2, a protein reagent that prevents natural apoptosis. These

reagents were evaluated positively and negatively. This reagent was used to evaluate liver changes in patients who died from fatty liver hepatitis, and in all 20 patients, 100% of the results were negative.

The level of CD20 in the liver is assessed by an increase in B-lymphocytes. The indicators of this reagent were determined through positive and negative indicators. All 20 selected patients showed positive reaction stages. Chronic inflammation of the liver in patients who died from hepatic-fatty hepatitis is associated with an increase in the number of lymphocytes and liver failure in patients with hepatocyte dysfunction.




Fig. 6. Positive reaction of the CD20 reagent for liver B-lymphocytes in fatty liver. The Dab coloring is chromogenic. Lens 20-Eyepiece 40.

In the cell complex, indicating the main level of activity of CD3 T-lymphocytes, the values of this reagent were assessed by positive and negative indicators. Positive reactions were found

in all 20 selected patients with fatty liver hepatitis, mainly due to the accumulation of a large number of lymphocytes around hepatocytes due to severe inflammation.





Fig. 7. Positive reaction of the CD3 reagent for liver T-lymphocytes in fatty liver. The Dab coloring is chromogenic. Lens 20-Eyepiece 40.

In an immunohistochemical study of patients with fatty hepatitis, it was concluded that intrahepatic cholestasis and preeclampsia, as well as the Ki-67 reagent, showed a low positive response rate of 2-8% in all patients, and high results of positive reactions were not observed.

Bcl-2 reagent test was negative in all patients. Samples with CD20 and CD3 reagents showed a positive reaction of CD20 and CD3 reagents in all patients due to a high inflammatory process of lymphocytes around hepatocytes in hepatic fatty hepatitis.

**Diagram 3.**

The results of immunohistochemical study in fatty liver №20.





**Conclusion**

The major diseases leading to liver failure in and resulting in maternal mortality include intrahepatic cholestasis, preeclampsia, and death due to fatty liver disease, which are currently seen in many. Liver failure is the leading cause of death. Our main goal was to study changes in the liver during immunohistochemical studies using Ki-67, Bcl-2, CD20 and CD3 reagents. The results of the study using the Ki-67 reagent showed that all patients had results with a low positive response rate of up to 2-8%, while there were no results with a medium and high positive response rate. As a result of the study conducted using the Bcl-2 reagent, all patients had negative reaction results, while 3 groups did not show any positive reaction results. Studies conducted with CD20 and CD3 reagents showed that in all three groups, a large number of lymphocytes accumulate around hepatocytes due to strong foci of inflammation and, as a result, makes it difficult for hepatocytes to perform their function and, as a result, leads to liver failure, which is one of the leading causes of maternal death.

**LIST OF REFERENCES:**

1. Загидуллина В.М., Рыжова А.С. Материнская смертность, как интегральный показатель, отражающий здоровье женщин // *Вопр. экономики и права*. 2015. № 83. С. 163-166.
2. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза / В. Т. Ивашкин [и др.] // *Рос. журн. Гастроэнтерол. гепатол. колопроктол.* – 2016. – Том 25, №2. – С. 41-57.
3. Маев И.В., Андреев Д.Н., Дичева Д.Т., Казначеева Т.В., Кунькина Ю.Б. Внутрпеченочный холестаз беременных. Пособие для врачей. – М.: Прима Принт, 2017.
4. Пальгова Л.К., Мозговая Е.В., Жесткова Н.В., Вишневецкая Е.Е., Пазенко Е.В. *Болезни печени и беременность. Анализ актуальных клинических рекомендаций и собственный опыт. Часть первая. Болезни печени, связанные с беременностью.* // *Экспериментальная и клиническая гастроэнтерология*. 2018;151(3): 105-114.
5. Пальгова Л.К. *Болезни печени, связанные с беременностью: Клинические рекомендации общества акушеров – гинекологов Санкт-Петербурга и СЗФО и Санкт-Петербургского общества гастроэнтерологов, гепатологов и диетологов* / Л.К. Пальгова, Е.В. Мозговая, Н.В. Жесткова, Э.К. Айламазяна «ред» – СПб.: Эко-Вектор, 2017. – 47 с.
6. Kobayashi T., Minami S., Mitani A., Tanizaki Y. Booka M., Okutani T., et al. Acute fatty liver of pregnancy associated with fetal mitochondrial trifunctional protein deficiency. // *J. Obstet. Gynaecol. Res.* 2015; 41(5): 799-802.
7. ACG Clinical Guideline: Liver Disease and Pregnancy *American Journal of Gastroenterology*: February 2016 – Volume 111 – Issue 2 – p 176-194.
8. Cardoso F.S., Marcelino P., Bagulho L., Karvellas C.J. Acute liver failure: An up-to-date approach. // *J. Crit. Care.* 2017; 39: 25-30.
9. Flamm S.L., Yang Y.X., Singh S., Falck-Ytter Y.T. AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guidelines for the Diagnosis and Management of Acute Liver Failure. // *Gastroenterology*. 2017; 152(3): 644-
10. Thawley V. Acute Liver Injury and Failure. *Vet. Clin. North Am. Small Anim. Pract.* 2017; 47(3): 617-30.
11. Wijampreecha K, Thongprayoon C, Sanguankeo A, Upala S, Ungprasert P, Cheungpasitporn W. Hepatitis C infection and intrahepatic cholestasis of pregnancy: A systematic review and meta-analysis. *Clin Res Hepatol. Gastroenterol.* 2016; 41: 39-45.
12. Zhou D.X., Bian X.Y., Cheng X.Y., Xu P., Zhang Y.F., Zhong J.X., et al. Late gestational liver dysfunction and its impact on pregnancy outcomes. *Clin. Exp. Obstet. Gynecol.* 2016; 43(3): 417-21.
13. Zheng J. SARS-CoV-2: An Emerging Coronavirus that Causes a Global Treat. *Int. J. Biol. Sci.* 2020;16:1678–1685.[CrossRef]

Entered 09.03.202